The influence of bromfenac on the pharmacokinetics and pharmacodynamic responses to glyburide in diabetic subjects

Pharmacotherapy

Volumn 17, Issue 4, 1997, Pages 783-790

  Boni, Joseph P ^a,b   Cevallos, William H ^a   DeCleene, Sheryl ^a   Korth Bradley, Joan M ^a  

^a WYETH AYERST RESEARCH   (United States)

^b NONE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

BROMFENAC; GLIBENCLAMIDE;

ADULT; AGED; AREA UNDER THE CURVE; ARTICLE; CLINICAL ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; CROSSOVER PROCEDURE; DOUBLE BLIND PROCEDURE; DRUG ABSORPTION; DRUG BLOOD LEVEL; DRUG CLEARANCE; DRUG EFFECT; DRUG EFFICACY; GLUCOSE BLOOD LEVEL; HUMAN; MALE; NON INSULIN DEPENDENT DIABETES MELLITUS; ORAL DRUG ADMINISTRATION; RANDOMIZED CONTROLLED TRIAL;

ADULT; AGED; ANALGESICS; AREA UNDER CURVE; BENZOPHENONES; BIOLOGICAL AVAILABILITY; BLOOD GLUCOSE; BROMOBENZENES; CROSS-OVER STUDIES; DIABETES MELLITUS, TYPE 2; DOUBLE-BLIND METHOD; DRUG INTERACTIONS; DRUG THERAPY, COMBINATION; FEMALE; GLYBURIDE; HALF-LIFE; HUMANS; HYPOGLYCEMIC AGENTS; MALE; METABOLIC CLEARANCE RATE; MIDDLE AGED;

EID: 0030802582     PISSN: 02770008     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (26)

1. Sancilio LF, Nolan, JC, Wagner, LE, Ward, JW. The analgesic and anti-inflammatory activity and pharmacologic properties of bromfenac. Arzneimittelforschung 1987;37:513-19.
2. Verbeeck RK, Blackburn JL, Loewen GR. Clinical pharmacokinetics of non-steroidal anti-inflammatory drugs. Clin Pharmacokinet 1983;8:297-331.
3. Feldman JM. Glyburide: a second-generation sulfonylurea hypoglycemic agent. History, chemistry, metabolism, pharmacokinetics, clinical use, and adverse effects. Pharmacotherapy 1985;5:43-62.
4. Giugliano D. Acetylsalicylic acid in diabetes. Lancet 1981;1:560.
5. Hansen JM, Christensen LK. Drug interactions with oral sulphonylurea hypoglycemic drugs. Drugs 1977;13:24-34.
6. Brown KF, Crooks MJ. Displacement of tolbutamide, glibenclamide and chlorpropamide from serum albumin by anionic drugs. Biochem Pharmacol 1976;25:1175-8.
7. Richardson T, Foster J, Mawer GE. Enhancement by sodium salicylate of the blood glucose lowering effect of chlorpropamide drug interaction or summation of similar effects? Br J Clin Pharmacol 1986;22:43-8.
8. Pond SM, Birkett DJ, Wade DN. Mechanisms of inhibition of tolbutamide metabolism: phenylbutazone, oxyphenbutazone, sulphenazole. Clin Pharmacol Ther 1977;22:573-9.
9. Muller R. The clinical evaluation of an oral antidiabetic drug. Aust N Z J Med 1971;1(suppl)2:39-46.
10. Field JB, Ohta M, Boyle C, Remer A. Potentiation of acetohexamide hypoglycemia by phenylbutazone. N Engl J Med 1967;277:889-99.
11. Shah SJ, Bhandarkar SD, Satoskar RS. Drug interaction between chlorpropamide and nonsteroidal anti-inflammatory drugs, ibuprofen and phenylbutazone. Int J Clin Pharmacol 1984;22:470-2.
12. Whiting B, Williams RL, Lorenzi M, Varady JC, Robins DS. Effect of naproxen on glucose metabolism and tolbutamide kinetics and dynamics in maturity onset diabetics. Br J Clin Pharmacol 1981;11:295-302.
13. Rainer F, Ulreich A, Klein G. Zur Frage der Interaktionen von nichtsteroidalen antirheumatika mit Kumarinderivaten, oralen Antidiabetika und anderen Pharmaka. Therapiewoche 1977;29:6834-9.
14. Stoeckel K, Trueb V, Dubach UC, Heintz RC, Ascalone V. Lack of effect of tenoxicam on glibornuride kinetics and response. Br J Clin Pharmacol 1985;19:249-54.
15. Chlud K. Investigations into possible interactions between diclofenac and glibenclamide. Z Rheum 1976;35:377-82.
16. Fowler PD. Diclofenac sodium (Voltarol): drug interactions and special studies. Rheumatol Rehabil 1979;17(suppl 2):60-8.
17. Chlud K, Kaik B. Clinical studies of the interaction between tolmetin and glibenclamide. Int J Clin Pharmacol 1977;15:409-10.
18. Osman MA, Dunning LK, Cheng LK, Wright GJ. Determination of bromfenac in plasma by high-performance liquid chromatography. J Chromatogr 1989;48:452-8.
19. Boudinot FD, Jusko WJ. Fluid shifts and other factors affecting plasma protein binding of prednisolone by equilibrium dialysis. J Pharm Sci 1984;73;774-80.
20. Schmidt FH. Blood glucose levels in capillary blood of adults assessed by the hexokinase method. Klin Wochenschr 1973;51:520-2.
21. Jusko WJ. Guidelines for collection and analysis of pharmacokinetic data. In: Evans WE, Schentag JJ, Jusko WJ, eds. Applied pharmacokinetics: principles of therapeutic drug monitoring, 3rd ed. Vancouver, WA: Applied Therapeutics, 1992:2-1-43.
22. Gibaldi M, Perrier D. Appendix D: estimation of areas. Pharmacokinetics, 2nd ed. New York: Marcel Dekker, 1982:445-9.
23. SAS Institute. SAS/STAT user's guide, version 4. Cary, NC: Author, 1990.
24. Zhi J, Melia A, Koss-Twardy S, et al. The influence of orlistat on the pharmacokinetics and pharmacodynamics of glyburide in healthy volunteers. J Clin Pharmacol 1995;35:521-5.
25. Fleishaker JC, Phillips JP. Evaluation of a potential interaction between erythromycin and glyburide in diabetic volunteers. J Clin Pharmacol 1991;31:259-62.
26. Coppack SW, Lant AF, McIntosh CS, Rodgers AV. Pharmacokinetic and pharmacodynamic studies of glibenclamide in non-insulin dependent diabetes mellitus. Br J Clin Pharmacol 1990;29:673-84.